Close Menu

NEW YORK (GenomeWeb) – Luminex announced today it has licensed the Xtreme Chain Reaction nucleic acid amplification technology from XCR Diagnostics.

The XCR technology enables rapid thermal cycling protocols in order to reduce assay turnaround times compared to traditional PCR.

"We look forward to leveraging the benefits that the XCR technology can bring to our future molecular diagnostics portfolio," Luminex President and CEO Homi Shamir said in a statement.

Financial terms for the non-exclusive, worldwide licensing agreement were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Feb
23
Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Feb
24
Sponsored by
SCHOTT MINIFAB

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints.